Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sang Hyuk | - |
dc.contributor.author | Kim, Seung Hwan | - |
dc.contributor.author | Nam, Taek Min | - |
dc.contributor.author | Jang, Ji Hwan | - |
dc.contributor.author | Kim, Kyu Hong | - |
dc.contributor.author | Lee, Young-Sam | - |
dc.contributor.author | Kim, Minseok S. | - |
dc.contributor.author | Kim, Mee-Seon | - |
dc.contributor.author | Jin, Sung Yup | - |
dc.contributor.author | Lee, Moonok | - |
dc.contributor.author | Lee, Sung-Hun | - |
dc.contributor.author | Kim, Young Zoon | - |
dc.date.accessioned | 2024-01-30T02:40:16Z | - |
dc.date.available | 2024-01-30T02:40:16Z | - |
dc.date.created | 2023-09-01 | - |
dc.date.issued | 2023-08 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11750/47706 | - |
dc.description.abstract | BACKGROUND: This study aimed to identify the specific T cell co-stimulatory and co-inhibitory factors that play prognostic roles in patients with glioblastoma. Additionally, the unique histone H3 modification enzymes that regulate the expression levels of these specific co-stimulatory and co-inhibitory factors were investigated. METHODS: The medical records of 84 patients newly diagnosed with glioblastoma at our institution from January 2006 to December 2020 were retrospectively reviewed. Immunohistochemical (IHC) staining for T cell co-stimulatory factors (CD27, CD28, CD137, OX40, and ICOS), T cell co-inhibitory factors (CTLA4, PD1, PD-L1, TIM3, and CD200R), and histone H3 lysine modification enzymes (MLL4, RIZ, EZH1, NSD2, KDM5c, JMJD1a, UTX, and JMJD5) was performed on archived paraffin-embedded tissues obtained by biopsy or resection. Quantitative real time-polymerase chain reaction (qRT-PCR) was performed for specific factors, which demonstrated causal relationships, in order to validate the findings of the IHC examinations. RESULTS: The mean follow-up duration was 27.5 months (range, 4.1-43.5 months). During this period, 76 patients (90.5%) died, and the mean OS was 19.4 months (95% confidence interval, 16.3-20.9 months). Linear positive correlations were observed between the expression levels of CD28 and JMJD1a (R2 linear = 0.982) and those of CD137 and UTX (R2 linear = 1.528). Alternatively, significant negative correlations were observed between the expression levels of CTLA4 and RIZ (R2 linear = -1.746) and those of PD-L1 and EZH1 (R2 linear = -2.118); these relationships were confirmed by qRT-PCR. In the multivariate analysis, increased expression levels of CD28 (P = 0.042), and CD137 (P = 0.009), and decreased expression levels of CTLA4 (P = 0.003), PD-L1 (P = 0.020), and EZH1 (P = 0.040) were significantly associated with longer survival. CONCLUSION: These findings suggest that the expression of certain T cell co-stimulatory factors, such as CD28 and CD 137, and co-inhibitory factors, such as CTLA4 and PD-L1 are associated with prognosis of glioblastoma patients. © 2023 The Korean Academy of Medical Sciences. | - |
dc.language | English | - |
dc.publisher | 대한의학회 | - |
dc.title | Epigenetic Regulation of the Expression of T Cell Stimulatory and Inhibitory Factors by Histone H3 Lysine Modification Enzymes and Its Prognostic Roles in Glioblastoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.3346/jkms.2023.38.e258 | - |
dc.identifier.scopusid | 2-s2.0-85168519227 | - |
dc.identifier.bibliographicCitation | Journal of Korean Medical Science, v.38, no.33 | - |
dc.description.isOpenAccess | TRUE | - |
dc.subject.keywordAuthor | Glioblastoma | - |
dc.subject.keywordAuthor | Epigenome | - |
dc.subject.keywordAuthor | Histone Modification | - |
dc.subject.keywordAuthor | T Cell | - |
dc.subject.keywordAuthor | Immunology | - |
dc.subject.keywordAuthor | Oncology | - |
dc.subject.keywordPlus | TUMOR-INFILTRATING LYMPHOCYTES | - |
dc.subject.keywordPlus | CENTRAL-NERVOUS-SYSTEM | - |
dc.subject.keywordPlus | HODGKIN LYMPHOMA | - |
dc.subject.keywordPlus | DNA METHYLATION | - |
dc.subject.keywordPlus | PD-L1 | - |
dc.subject.keywordPlus | BLOCKADE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | AMPLIFICATION | - |
dc.citation.number | 33 | - |
dc.citation.title | Journal of Korean Medical Science | - |
dc.citation.volume | 38 | - |